We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SEAT:NASDAQVivid Seats Inc. Analysis

Data as of 2026-04-30 - not real-time

$6.24

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Vivid Seats (SEAT) is trading at $6.24, well below its 20‑day SMA of $6.89 and 50‑day SMA of $6.45, indicating short‑term weakness. The RSI sits at 45.5, suggesting a neutral momentum, while the MACD line sits below its signal, flagging a bearish technical bias. Volatility is extreme at roughly 101% over the past 30 days and a computed beta of 2.08 points to a stock that swings far more than the market. Fundamentally, the company is in distress: revenue has fallen 36.5%, margins are deeply negative (operating margin –14.2%, profit margin –75.2%), and cash flow is heavily negative with $78.6 M in free‑cash‑flow deficit. The balance sheet shows $406 M of debt against modest cash of $102 M and a negative book value per share of –$7.91. Recent headlines report a sharp share‑price plunge following a bleak quarterly report, reinforcing the downside pressure.
Despite a low price‑to‑sales multiple of 0.12 and an implied upside of ~53% from current levels to the median analyst target of $9, the combination of deteriorating fundamentals, high volatility, and bearish technical signals suggest that any upside is speculative and comes with substantial risk.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Bearish MACD histogram and proximity to support level
  • Extreme 30‑day volatility and high beta
  • Negative earnings surprise and share‑price plunge in news

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Low price‑to‑sales ratio suggesting cheapness
  • Continued negative cash flow and margins
  • Potential for modest recovery if revenue stabilises

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • Sustained structural deficits (negative EPS, negative book value)
  • High debt load relative to cash and earnings
  • Persistent high volatility and weak industry fundamentals

Key Metrics & Analysis

Financial Health

Revenue Growth-36.50%
Profit Margin-75.21%
P/E Ratio-1.8
ROE-272.82%
ROA-3.11%
P/B Ratio-0.8
Op. Cash Flow$-91599000
Free Cash Flow$-78614128
Industry P/E18.7

Technical Analysis

TrendNeutral
RSI45.6
Support$5.90
Resistance$8.29
MA 20$6.89
MA 50$6.45
MA 200$11.69
MACDBearish
VolumeStable
Fear & Greed Index88.25

Valuation

Target Price$9.58
Upside/Downside53.55%
GradeUndervalued
TypeValue

Risk Assessment

Beta2.08
Volatility100.92%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.